AK CLRN1
Alternative Names: AK-CLRN1Latest Information Update: 05 Dec 2022
At a glance
- Originator Akouos
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Usher syndromes
Most Recent Events
- 01 Dec 2022 Akouos has been acquired by Eli Lilly and Company
- 27 Aug 2021 Preclinical trials in Usher syndromes in USA (Parenteral) (Akouos pipeline, August 2021)
- 27 Aug 2021 Akouos plans a pre-IND meeting for Usher syndromes (Akouos, August 2021)